Evaluate real-world progression-free survival
Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib • Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) • Patients who received at least one dose of the treatment with sotorasib as part of the French Early Access Program (ATU program) • Patients who were informed about the study and do not object for their data to be collected • Age > 18 years
Intérêt public
IFCT
Durée conforme à la réglementation